LifeSciences BC > News > Member Announcements > Page 2

ACCEL-RX ADDS INVERSAGO PHARMA TO INVESTMENT PORTFOLIO

July 25, 2018

Company Targets Cannabinoid-1 Receptors to Treat Range of Metabolic Disorders VANCOUVER, British Columbia, 25 July, 2018 – Accel-Rx, Canada’s national health sciences accelerator, continues to build its portfolio of promising next-gen Canadian start-ups with an investment in Inversago Pharma.  Accel-Rx joins the $7 million Series A round, which also includes co-investors Genesys Capital, AmorChem, Juvenile … Continue reading ACCEL-RX ADDS INVERSAGO PHARMA TO INVESTMENT PORTFOLIO

Aequus Extends and Enhances Commercial Agreement to Promote Vistitan in Canada

July 19, 2018
Aequus Pharmaceuticals Inc

VANCOUVER, BC. July 16, 2018 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), is pleased to announce that it has agreed to new terms for its promotional service agreement with Sandoz on PRVistitan™ (“Vistitan”) with improved economics and a term extension of an additional year. Aequus began promotional efforts in May 2016 for … Continue reading Aequus Extends and Enhances Commercial Agreement to Promote Vistitan in Canada

Aequus Announces Expansion of Market Opportunity for its Long Acting Anti-Nausea Transdermal Patch

July 19, 2018
Aequus Pharmaceuticals

  Aequus Announces Expansion of Market Opportunity for its Long Acting Anti-Nausea Transdermal Patch   European market represents latest opportunity for anti-nausea transdermal patch in development by Aequus Pharmaceuticals Inc. VANCOUVER, BC July 19, 2018 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce a recent expansion of … Continue reading Aequus Announces Expansion of Market Opportunity for its Long Acting Anti-Nausea Transdermal Patch

Arbutus to Report Second Quarter 2018 Financial Results

July 19, 2018
Arbutus Biopharma Corporation

WARMINSTER, Pa., July 19, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its second quarter financial results, conference call and webcast for Thursday, August 2, 2018. The schedule for the press release and conference call/webcast are as follows: • Q2 2018 Press Release: August 2, … Continue reading Arbutus to Report Second Quarter 2018 Financial Results

Xenon Pharmaceuticals Announces At-The-Market Equity Offering

July 17, 2018
Xenon Pharmaceuticals Inc. 

BURNABY, British Columbia, July 12, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, announced today that it has entered into an at-the-market equity offering sales agreement with Jefferies and Stifel, effective as of July 11, 2018, under which Xenon may sell its common shares, from time to time, for up to … Continue reading Xenon Pharmaceuticals Announces At-The-Market Equity Offering

RepliCel Life Sciences Announces Signed Licensing and Co-Development Deal for Greater China

July 11, 2018
Replicel Life Sciences

Skin rejuvenation and tendon regeneration products to be commercialized in Greater China in partnership with YOFOTO (China) Health Industry Co. Ltd VANCOUVER and NINGBO, Zhejiang Province, China, July 11, 2018 /PRNewswire/ – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has now signed definitive … Continue reading RepliCel Life Sciences Announces Signed Licensing and Co-Development Deal for Greater China

Arbutus Presents Corporate Update on Key Milestones

July 10, 2018
Arbutus Biopharma Corporation

First Subject Dosed in Phase 1 Study of AB-506, Arbutus’ Second-Generation Capsid Inhibitor All-Oral Combination Study of AB-506 and AB-452 Expected in 2019 HBsAg Reduction Data from ARB-1467 Expected in Q4 Arbutus Spinout Genevant Enters Transformative Partnership with Leading mRNA Therapeutics Company BioNTech WARMINSTER, Pa., July 10, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), … Continue reading Arbutus Presents Corporate Update on Key Milestones

Health Canada Cleared EmeTerm Anti-Nausea Wristband and HeadaTerm Anti-Migraine Head Patch

July 5, 2018
WAT Medical Enterprises Inc.

Shortly after WAT Medical’s leading product to treat nausea-induced vomiting, EmeTerm, received its FDA clearance earlier in April, it has now also received official clearance from Health Canada. Health Canada ensures all of its certified medical products are of the highest quality and are able to provide the best care for patients to improve their … Continue reading Health Canada Cleared EmeTerm Anti-Nausea Wristband and HeadaTerm Anti-Migraine Head Patch

ACCEL-RX PORTFOLIO COMPANIES SECURE FOLLOW-ON FUNDING

July 3, 2018
Accel-Rx Health Sciences

KisoJi, SoundBite and Zucara Collectively Raise $40 Million CDN VANCOUVER, July 3, 2018 — Accel-Rx, Canada’s national health sciences accelerator, announced today that three of its portfolio companies have recently secured a total of $40 million CDN in follow-on funding to advance the development and commercialization of their technologies. KisoJi Biotechnology completed a significant Series … Continue reading ACCEL-RX PORTFOLIO COMPANIES SECURE FOLLOW-ON FUNDING

League and Molecular You Partner to Provide Employees with Personalized Health Assessments for Early Detection and Preventive Healthcare

June 28, 2018

Opens up personal health assessments to the whole workforce Vancouver, BC – June 28, 2018 — League Inc., the disruptive health benefits platform, and Molecular You, the personalized health company, are joining forces to give employees in North America more control over their health with access to comprehensive annual health assessments. While executives in many … Continue reading League and Molecular You Partner to Provide Employees with Personalized Health Assessments for Early Detection and Preventive Healthcare